Cargando…

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

PD-L1 expression is a feature of Epstein-Barr virus (EBV) associated malignancies such as nasopharyngeal carcinoma (NPC). Here, we found that EBV-induced latent membrane protein 1 (LMP1) and IFN-γ pathways cooperate to regulate programmed cell death protein 1 ligand (PD-L1). Expression of PD-L1 was...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Wenfeng, Zhang, Jianwei, Hong, Shaodong, Zhan, Jianhua, Chen, Nan, Qin, Tao, Tang, Yanna, Zhang, Yaxiong, Kang, Shiyang, Zhou, Ting, Wu, Xuan, Liang, Wenhua, Hu, Zhihuang, Ma, Yuxiang, Zhao, Yuanyuan, Tian, Ying, Yang, Yunpeng, Xue, Cong, Yan, Yue, Hou, Xue, Huang, Peiyu, Huang, Yan, Zhao, Hongyun, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322961/
https://www.ncbi.nlm.nih.gov/pubmed/25361008
_version_ 1782356466087231488
author Fang, Wenfeng
Zhang, Jianwei
Hong, Shaodong
Zhan, Jianhua
Chen, Nan
Qin, Tao
Tang, Yanna
Zhang, Yaxiong
Kang, Shiyang
Zhou, Ting
Wu, Xuan
Liang, Wenhua
Hu, Zhihuang
Ma, Yuxiang
Zhao, Yuanyuan
Tian, Ying
Yang, Yunpeng
Xue, Cong
Yan, Yue
Hou, Xue
Huang, Peiyu
Huang, Yan
Zhao, Hongyun
Zhang, Li
author_facet Fang, Wenfeng
Zhang, Jianwei
Hong, Shaodong
Zhan, Jianhua
Chen, Nan
Qin, Tao
Tang, Yanna
Zhang, Yaxiong
Kang, Shiyang
Zhou, Ting
Wu, Xuan
Liang, Wenhua
Hu, Zhihuang
Ma, Yuxiang
Zhao, Yuanyuan
Tian, Ying
Yang, Yunpeng
Xue, Cong
Yan, Yue
Hou, Xue
Huang, Peiyu
Huang, Yan
Zhao, Hongyun
Zhang, Li
author_sort Fang, Wenfeng
collection PubMed
description PD-L1 expression is a feature of Epstein-Barr virus (EBV) associated malignancies such as nasopharyngeal carcinoma (NPC). Here, we found that EBV-induced latent membrane protein 1 (LMP1) and IFN-γ pathways cooperate to regulate programmed cell death protein 1 ligand (PD-L1). Expression of PD-L1 was higher in EBV positive NPC cell lines compared with EBV negative cell lines. PD-L1 expression could be increased by exogenous and endogenous induction of LMP1 induced PD-L1. In agreement, expression of PD-L1 was suppressed by knocking down LMP1 in EBV positive cell lines. We further demonstrated that LMP1 up-regulated PD-L1 through STAT3, AP-1, and NF-κB pathways. Besides, IFN-γ was independent of but synergetic with LMP1 in up-regulating PD-L1 in NPC. Furthermore, we showed that PD-L1 was associated with worse disease-free survival in NPC patients. These results imply that blocking both the LMP1 oncogenic pathway and PD-1/PD-L1 checkpoints may be a promising therapeutic approach for EBV positive NPC patients.
format Online
Article
Text
id pubmed-4322961
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-43229612015-02-10 EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy Fang, Wenfeng Zhang, Jianwei Hong, Shaodong Zhan, Jianhua Chen, Nan Qin, Tao Tang, Yanna Zhang, Yaxiong Kang, Shiyang Zhou, Ting Wu, Xuan Liang, Wenhua Hu, Zhihuang Ma, Yuxiang Zhao, Yuanyuan Tian, Ying Yang, Yunpeng Xue, Cong Yan, Yue Hou, Xue Huang, Peiyu Huang, Yan Zhao, Hongyun Zhang, Li Oncotarget Research Paper PD-L1 expression is a feature of Epstein-Barr virus (EBV) associated malignancies such as nasopharyngeal carcinoma (NPC). Here, we found that EBV-induced latent membrane protein 1 (LMP1) and IFN-γ pathways cooperate to regulate programmed cell death protein 1 ligand (PD-L1). Expression of PD-L1 was higher in EBV positive NPC cell lines compared with EBV negative cell lines. PD-L1 expression could be increased by exogenous and endogenous induction of LMP1 induced PD-L1. In agreement, expression of PD-L1 was suppressed by knocking down LMP1 in EBV positive cell lines. We further demonstrated that LMP1 up-regulated PD-L1 through STAT3, AP-1, and NF-κB pathways. Besides, IFN-γ was independent of but synergetic with LMP1 in up-regulating PD-L1 in NPC. Furthermore, we showed that PD-L1 was associated with worse disease-free survival in NPC patients. These results imply that blocking both the LMP1 oncogenic pathway and PD-1/PD-L1 checkpoints may be a promising therapeutic approach for EBV positive NPC patients. Impact Journals LLC 2014-10-21 /pmc/articles/PMC4322961/ /pubmed/25361008 Text en Copyright: © 2014 Fang et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Fang, Wenfeng
Zhang, Jianwei
Hong, Shaodong
Zhan, Jianhua
Chen, Nan
Qin, Tao
Tang, Yanna
Zhang, Yaxiong
Kang, Shiyang
Zhou, Ting
Wu, Xuan
Liang, Wenhua
Hu, Zhihuang
Ma, Yuxiang
Zhao, Yuanyuan
Tian, Ying
Yang, Yunpeng
Xue, Cong
Yan, Yue
Hou, Xue
Huang, Peiyu
Huang, Yan
Zhao, Hongyun
Zhang, Li
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
title EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
title_full EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
title_fullStr EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
title_full_unstemmed EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
title_short EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
title_sort ebv-driven lmp1 and ifn-γ up-regulate pd-l1 in nasopharyngeal carcinoma: implications for oncotargeted therapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322961/
https://www.ncbi.nlm.nih.gov/pubmed/25361008
work_keys_str_mv AT fangwenfeng ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT zhangjianwei ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT hongshaodong ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT zhanjianhua ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT chennan ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT qintao ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT tangyanna ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT zhangyaxiong ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT kangshiyang ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT zhouting ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT wuxuan ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT liangwenhua ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT huzhihuang ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT mayuxiang ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT zhaoyuanyuan ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT tianying ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT yangyunpeng ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT xuecong ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT yanyue ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT houxue ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT huangpeiyu ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT huangyan ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT zhaohongyun ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy
AT zhangli ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy